Helixmith Signs MOU for Joint Research on Cell and Gene Therapy with Catexcel and GI Cell

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 28th that it has signed a tripartite Memorandum of Understanding (MOU) with Catexcel and GI Cell for joint research on cell and gene therapy products.

(From left) Hong Cheon-pyo, CEO of GI Cell; Yoo Seung-shin, CEO of Helixmith; Seo Je-hee, CEO of Cartexel. / Photo by Helixmith

The signing ceremony held at the GI Cell headquarters located in Seongnam-si, Gyeonggi-do was attended by key officials including Helixmith CEO Yoo Seung-shin, Catexcel CEO Seo Je-hee, Center Director Chae Jin-ah, GI Cell CEO Hong Cheon-pyo, and President Min Byung-jo.

Under this MOU, the three companies will collaborate to identify candidate substances for cell and gene therapy products and cooperate in the manufacturing of clinical trial drugs and commercialization.

Based on Helixmith CGT Center (Cell & Gene Therapy Center)'s cell and gene therapy development and production technology and one-stop service, Catexcel's CAR-T cell therapy technology, and GI Cell's immune cell culture and freezing system, the three companies are expected to lead the cell and gene therapy market together.

Yoo Seung-shin, CEO of Helixmith, said, “Through this MOU, we expect to demonstrate differentiated competitiveness in the cell and gene therapy business,” adding, “We will continue to leap forward as a global gene therapy company representing Korea in the world market through various agreements with excellent companies.”

Seo Je-hee, CEO of Catexcel, said, “Through the convergence of Helixmith and Catexcel's advanced CAR gene engineering and delivery technology and GI Cell's differentiated immune cell culture technology, we expect to secure the CAR-NK cell therapy pipeline at an early stage.”

This content was produced with the assistance of AI translation services.